Cho Y - Search Results

1

Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer.

Nam GH, Kwon M, Jung H, Ko E, Kim SA, Choi Y, Song SJ, Kim S, Lee Y, Kim GB, Han J, Woo J, Cho Y, Jeong C, Park SY, Roberts TM, Cho YB, Kim IS. Nam GH, et al. Among authors: cho yb, cho y. J Immunother Cancer. 2021 Jul;9(7):e002474. doi: 10.1136/jitc-2021-002474. J Immunother Cancer. 2021. PMID: 34330763 Free PMC article.

2

Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab.

Lee J, Hong YS, Hong JY, Han SW, Kim TW, Kang HJ, Kim TY, Kim KP, Kim SH, Do IG, Kim KM, Sohn I, Park SH, Park JO, Lim HY, Cho YB, Lee WY, Yun SH, Kim HC, Park YS, Kang WK. Lee J, et al. Invest New Drugs. 2014 Jun;32(3):535-41. doi: 10.1007/s10637-014-0065-x. Epub 2014 Jan 28. Invest New Drugs. 2014. PMID: 24468885 Clinical Trial.

3

The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis.

Kim HS, Heo JS, Lee J, Lee JY, Lee MY, Lim SH, Lee WY, Kim SH, Park YA, Cho YB, Yun SH, Kim ST, Park JO, Lim HY, Choi YS, Kwon WI, Kim HC, Park YS. Kim HS, et al. BMC Cancer. 2016 Feb 18;16:120. doi: 10.1186/s12885-016-2141-4. BMC Cancer. 2016. PMID: 26887348 Free PMC article.

4

Crosstalk between CCL7 and CCR3 promotes metastasis of colon cancer cells via ERK-JNK signaling pathways.

Lee YS, Kim SY, Song SJ, Hong HK, Lee Y, Oh BY, Lee WY, Cho YB. Lee YS, et al. Among authors: cho yb. Oncotarget. 2016 Jun 14;7(24):36842-36853. doi: 10.18632/oncotarget.9209. Oncotarget. 2016. PMID: 27167205 Free PMC article.

5

Efficient primary culture model of patient‑derived tumor cells from colorectal cancer using a Rho‑associated protein kinase inhibitor and feeder cells.

Hong HK, Pyo DH, Kim TW, Yun NH, Lee YS, Song SJ, Lee WY, Cho YB. Hong HK, et al. Oncol Rep. 2019 Nov;42(5):2029-2038. doi: 10.3892/or.2019.7285. Epub 2019 Aug 20. Oncol Rep. 2019. PMID: 31432145

6

The FBW7-MCL-1 axis is key in M1 and M2 macrophage-related colon cancer cell progression: validating the immunotherapeutic value of targeting PI3Kγ.

Lee YS, Song SJ, Hong HK, Oh BY, Lee WY, Cho YB. Lee YS, et al. Exp Mol Med. 2020 May;52(5):815-831. doi: 10.1038/s12276-020-0436-7. Epub 2020 May 22. Exp Mol Med. 2020. PMID: 32444799 Free PMC article.

7

Expression of SLC22A18 regulates oxaliplatin resistance by modulating the ERK pathway in colorectal cancer.

Kim TW, Pyo DH, Ko E, Yun NH, Song SJ, Choi SM, Hong HK, Kim SH, Choi YL, Lee J, Lee WY, Cho YB. Kim TW, et al. Am J Cancer Res. 2022 Mar 15;12(3):1393-1408. eCollection 2022. Am J Cancer Res. 2022. PMID: 35411243 Free PMC article.

8

Characterization of SLC22A18 as a tumor suppressor and novel biomarker in colorectal cancer.

Jung Y, Jun Y, Lee HY, Kim S, Jung Y, Keum J, Lee YS, Cho YB, Lee S, Kim J. Jung Y, et al. Among authors: cho yb. Oncotarget. 2015 Sep 22;6(28):25368-80. doi: 10.18632/oncotarget.4681. Oncotarget. 2015. PMID: 26196590 Free PMC article.

9

Animal models of colorectal cancer with liver metastasis.

Oh BY, Hong HK, Lee WY, Cho YB. Oh BY, et al. Cancer Lett. 2017 Feb 28;387:114-120. doi: 10.1016/j.canlet.2016.01.048. Epub 2016 Feb 2. Cancer Lett. 2017. PMID: 26850374 Review.

10

Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer.

Joung JG, Oh BY, Hong HK, Al-Khalidi H, Al-Alem F, Lee HO, Bae JS, Kim J, Cha HU, Alotaibi M, Cho YB, Hassanain M, Park WY, Lee WY. Joung JG, et al. Clin Cancer Res. 2017 Dec 1;23(23):7209-7216. doi: 10.1158/1078-0432.CCR-17-0306. Epub 2017 Sep 22. Clin Cancer Res. 2017. PMID: 28939741

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

15,264 results

Search Page